Overall rank by patents
#3,875
Across all tracked assignees
USPTO PatentsView assignee record - 93 granted patents across 18 technology areas, active 2016–2025. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: C12N (MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA).
The verdict
Arrowhead holds 93 US patents across 18 technology areas, rank #3,875 of 50,000 tracked assignees.
Arrowhead Pharmaceuticals, Inc. has been granted 93 US utility patents between 2016 and 2025, placing Arrowhead Pharmaceuticals, Inc. at rank #3,875 across all assignees tracked by PlainPatent. This portfolio spans 18 distinct Cooperative Patent Classification (CPC) subclasses, averaging 21.7 claims per patent with primary concentration in C12N (MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA). As a US Corporation, Arrowhead Pharmaceuticals, Inc. is one of the more focused assignees in the PatentsView dataset. By volume, Arrowhead sits between Valeo Systemes DE Controle Moteur (94 patents, rank #3,871) and Chang GUNG University (93 patents, rank #3,879) - the closest US assignees by grant volume. The composite Innovation Score of 48.8/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Between 2020 and 2025 the company received 47 grants, compared with 46 in the 2015–2019 window, a +2% shift in five-year velocity. Steady filing volume suggests sustained innovation without dramatic pivots. The US Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. Arrowhead Pharmaceuticals, Inc.'s 21.7 average claims per patent reflects complex, broadly scoped inventions that are difficult for competitors to design around, while concentration in 18 subclasses points to a focused technical program. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Arrowhead Pharmaceuticals, Inc. against peers pursuing similar technology classes.
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
VALEO SYSTEMES DE CONTROLE MOTEUR
94 patents
WABCO Europe BVBA
94 patents
Wisk Aero LLC
94 patents
XIEON NETWORKS S.a.r.l.
94 patents
Avon Products, Inc.
93 patents
BLACKPIN INC.
93 patents
BUNDESDRUCKEREI GMBH
93 patents
CHANG GUNG UNIVERSITY
93 patents
Arrowhead Pharmaceuticals, Inc.
93 patents
What this shows Arrowhead holds 93 patents at rank #3,875, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
By rank, the assignees closest to #3,875 in granted patent volume.
Other assignees with the most granted patents in Arrowhead's primary technology class.
Arrowhead's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
49 Top 16% higher than 84% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Teal-shaded recent years (2020–present) versus the 2016–2019 baseline. Full figures in the table below.
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2016 | 11 | 11.8% |
| 2017 | 11 | 11.8% |
| 2018 | 15 | 16.1% |
| 2019 | 9 | 9.7% |
| 2020 | 11 | 11.8% |
| 2021 | 9 | 9.7% |
| 2022 | 7 | 7.5% |
| 2023 | 6 | 6.5% |
| 2024 | 9 | 9.7% |
| 2025 | 5 | 5.4% |
Top 15 of 18 technology areas
Overall rank by patents
#3,875
Across all tracked assignees
48.8 out of 100
How to use this portfolio
Arrowhead's 93 grants land it in the top 16% by Innovation Score, but volume alone doesn't tell you where the strength sits.
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.